作者: Horst Lindhofer , Juergen Hess , Peter Ruf
DOI: 10.1007/978-3-642-20910-9_16
关键词:
摘要: In the 1980s, two groups described in parallel and for first time T-cell-redirecting bispecific antibodies (bsAbs) elimination of tumor cells (Perez et al. 1985; Staerz "CR60">1985). vitro, this approach was extremely potent, highlighting superiority T-cell-induced compared to accessory cell-mediated killing. But major drawbacks hampered rapid transition new from preclinical investigations successful clinical trials market approval.